This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

News
On World Arthritis Day ‘Don’t Delay, Connect ... On World Arthritis Day ‘Don’t Delay, Connect Today’ Campaign ... (15 Oct 2018)
3D mammography detected 34% more breast ... “With breast tomosynthesis, 34 per cent more cancer tumours were ... (15 Oct 2018)
Breastfeeding protects infants from ...  A new study from the University of Helsinki shows that babies ... (15 Oct 2018)
Reduced risk of severe stroke for ... Physical activity not only reduces the risk of stroke. ... (15 Oct 2018)
Link between Gut Flora and Multiple ...  In multiple sclerosis, a defective response of the body’s own ... (15 Oct 2018)
Sunday, 07 October 2018 19:19

Antibiotic effective in breast cancer clinical trial Featured

Rate this item
(0 votes)

Scientists fighting cancer have carried out the first successful trial of the effects of the antibiotic Doxycycline on cancer reoccurrence in patients after surgery.

Breast cancer patients were given the orally-administered antibiotic for 14 days before surgery and almost all saw a significant drop in cancer stem cells, the aggressive cells that drive tumour recurrence.

Although small – restricted to 15 patients at the University Hospital in Pisa, Italy – the trial is highly significant, giving hope for the efficacy of cheap, over-the-counter drugs being used alongside standard treatments to prevent cancer regrowth.

Doxycycline is one of the most commonly-prescribed antibiotics, effective in treating pneumonia, sinusitis, chlamydia, syphilis, cholera and Lyme disease.

The research, reported in the journal Frontiers in Oncology, was led by Professors Michael Lisanti and Federica Sotgia at the University of Salford and supported by the Healthy Life Foundation, the Pisa Science Foundation and the Foxpoint Foundation.

Lisanti, chair of translational medicine, said: “We have very few FDA-approved drugs to target and reduce cancer stem cells, so to find that a drug that is effective, readily-available and costs just 10 pence per patient per day and is highly significant, particularly as around two-thirds of cancer deaths occur due to recurrence after initial treatment.”

The University of Salford specialises in discovering non-toxic remedies and repurposing approved drugs as complementary treatments for cancer.

In the trial, doxycycline was administered to 9 patients whilst a further 6 were observed as ‘controls’ (no treatment). Immuno-histochemical analysis was performed with known biomarkers of “stemness” (CD44, ALDH1), mitochondrial mass (TOMM20), cell proliferation (Ki67, p27), apoptosis (cleaved caspase-3) and neo-angiogenesis (CD31). For each patient, the analysis was performed both on pre-operative specimens (core-biopsies) and surgical specimens.

Post-doxycycline tumour samples demonstrated a statistically significant decrease in CD44 - between 17.65% and 66.67%, in 8 out of 9 patients treated. One patient showed a rise in CD44, by 15%. Overall, this represents a positive response rate of nearly 90%. Similar results were also obtained with ALDH1, another marker of stemness.

“What we infer here is that the stem cells selectively over-express key mitochondrial-related proteins, which means that if we can inhibit mitochondrial function we can disrupt the stem cells,” explained Prof Sotgia.

Because mitochondria evolved from bacteria, they explain, many classes of antibiotics including Doxycycline actually target mitochondria and inhibit the reproduction of stem cells. These latest observations, they say, are further evidence that mitochondria are both biomarkers and potential drug targets.

Professor Lisanti added: “Our ability to treat cancer can only be enhanced by utilising drugs that are not only cheap but also widely available. Since Doxycycline first became clinically available in 1967, its anti-cancer activity has been right under our nose, for more than 50 years.”




Source: The University of Salford
Full bibliographic information

Doxycycline, an inhibitor of mitochondrial biogenesis, effectively reduces cancer stem cells (CSCs) in early breast cancer patients: A clinical pilot study

Read 120 times Last modified on Tuesday, 09 October 2018 20:16

TheSynapse Videos

0
0
0
0
0
0

Latest news

Highlights

  • Interactive Discussion on Valsartan

     

     

    The Malta Medicines Authority in collaboration with the Superintendence
    of Public Health and the Department of Pharmacy University of Malta
    would like to cordially invite you to an interactive scientific discussion:

     

     


    THE VALSARTAN SAGA


    SCIENCE | MYTHS | REALITIES

     


    led by Professor Anthony Serracino Inglott

     


    Date: Wednesday 25 July 2018

     


    Time: 20:00
    Venue: Conference Room, Life Sciences Park, San Ġwann

     


    Refreshments will be served


    RSVP: info.medicinesauthority@gov.mt | 23439202

    Written on July 21, 2018
  • Les Laboratoires Servier - Job Vacancy
    Written on June 29, 2018 Read more...

Join

Connect with other Medical Professionals on fb in a closed facebook group

captcha  

Login

Template Settings

Theme Colors

Cyan Red Green Oranges Teal

Layout

Wide Boxed Framed Rounded
Patterns for Layour: Boxed, Framed, Rounded
Top
We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…